Finabiotech is a pioneering startup focused on revolutionizing the diagnosis and monitoring of bladder cancer. The company operates in the healthcare and biotechnology market, specifically targeting the genitourinary tract cancers. Bladder cancer is the second most common malignancy in this category, following prostate cancer. Finabiotech's primary product, UroBEST, offers a non-invasive diagnostic method that uses spontaneous urine samples to detect bladder cancer.

UroBEST employs RT qPCR technology, a widely used method in hospitals and laboratories, to measure genetic expression levels. This technology provides a reliable and easy-to-perform diagnostic tool with a sensitivity of 79.63% and a specificity of 93.53%. Sensitivity refers to the test's ability to correctly identify those with the disease, while specificity refers to its ability to correctly identify those without the disease. These metrics indicate that UroBEST is both accurate and reliable.

The company serves healthcare providers, including hospitals, clinics, and specialized cancer treatment centers. By offering a non-invasive alternative to traditional diagnostic methods like cystoscopy and cytology, which are costly and uncomfortable for patients, Finabiotech aims to improve patient comfort and reduce healthcare costs. Traditional methods require transurethral access and frequent monitoring, which can be invasive and risky.

Finabiotech's business model revolves around selling its diagnostic kits and related services to healthcare institutions. The company generates revenue through the sale of these kits and possibly through partnerships with medical facilities and research institutions. By converting cutting-edge research into practical diagnostic tools, Finabiotech is making significant strides in the early detection and ongoing monitoring of bladder cancer.

In summary, Finabiotech is a healthcare startup specializing in non-invasive bladder cancer diagnostics, serving medical professionals and institutions with its innovative UroBEST product.

Keywords: Finabiotech, bladder cancer, non-invasive, UroBEST, RT qPCR, healthcare, diagnostics, biotechnology, patient comfort, medical innovation.